FY2026 Earnings Estimate for Adagene Issued By HC Wainwright

Key Points

• HC Wainwright lowered Adagene’s FY2026 EPS estimate to a loss of $0.43 per share from $0.37, while maintaining a “Buy” rating and $7.00 price target.
• Adagene shares fell 9.2% and opened at $2.97, below their 50-day and 200-day moving averages. Analysts’ overall consensus remains “Moderate Buy,” with an average price target of $8.67.
• CEO Peter Luo increased his stake by purchasing 22,966 shares, while Renaissance Technologies initiated a 34,533-share position; insiders collectively own 21.20% of the company.

Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Free Report) - Stock analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Adagene in a research note issued on Monday, September 14th. HC Wainwright analyst A. He now forecasts that the company will post earnings of ($0.43) per share for the year, down from their previous estimate of ($0.37). HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Adagene's current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Adagene's FY2027 earnings at ($0.42) EPS, FY2028 earnings at ($0.70) EPS, FY2029 earnings at ($1.07) EPS and FY2030 earnings at ($0.87) EPS.

A number of other equities research analysts have also commented on ADAG. Guggenheim reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Adagene in a research note on Tuesday, July 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Adagene in a research note on Friday, July 17th. Finally, Chardan Capital started coverage on shares of Adagene in a research report on Thursday, September 10th. They set a "buy" rating and a $9.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Adagene has a consensus rating of "Moderate Buy" and a consensus price target of $8.67.

Adagene Trading Down 9.2%

Shares of ADAG stock opened at $2.97 on Wednesday. The stock has a 50-day moving average of $3.71 and a 200-day moving average of $3.72. Adagene has a 1-year low of $1.30 and a 1-year high of $4.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.02 and a quick ratio of 3.07.

Institutional Trading of Adagene

A hedge fund recently bought a new stake in Adagene stock. Renaissance Technologies LLC bought a new position in shares of Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 34,533 shares of the company's stock, valued at approximately $135,000. Renaissance Technologies LLC owned approximately 0.07% of Adagene at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.51% of the company's stock.

Insider Activity

In related news, CEO Peter Luo purchased 22,966 shares of the firm's stock in a transaction dated Tuesday, August 4th. The stock was bought at an average price of $3.65 per share, for a total transaction of $83,825.90. Following the purchase, the chief executive officer directly owned 67,966 shares in the company, valued at approximately $248,075.90. This trade represents a 51.04% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have purchased 25,245 shares of company stock worth $92,344. Company insiders own 21.20% of the company's stock.

Adagene Company Profile

Adagene Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines for cancer and other serious diseases. The company combines computational antibody-design capabilities with laboratory-based discovery and development platforms to create differentiated therapeutic candidates.

Adagene's technology portfolio includes its SAFEbody platform, which is designed to mask antibody binding sites until the medicines reach the tumor microenvironment, potentially improving tumor selectivity and reducing activity in healthy tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.